- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03673306
Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
14. september 2018 opdateret af: Jules Bordet Institute
A Multicenter Retrospective Study on the Prognostic Impact of Pregnancy in Women With History of BRCA Mutated Breast Cancer
The present study aims at refining the understanding of the effect of pregnancy on breast cancer outcomes in the specific population of BRCA mutated patients with known history of breast cancer.
Studieoversigt
Status
Aktiv, ikke rekrutterende
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Forventet)
2200
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Brussels, Belgien
- Institut Jules Bordet
-
Brussels, Belgien
- Cliniques Universitaires Saint-Luc UCL
-
Leuven, Belgien
- University hospitals Leuven, KU Leuven
-
-
-
-
-
São Paulo, Brasilien
- Cancer Institute ICESP
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana-Farber Cancer Institute
-
-
-
-
-
Bordeaux, Frankrig
- Bergonie Institute
-
Lyon, Frankrig
- Leon Berard Cancer Center
-
Paris, Frankrig
- Hopital Saint Louis
-
Paris, Frankrig
- Institut Curie
-
Rouen, Frankrig
- Centre Henri Becquerel
-
Villejuif, Frankrig
- Institut Gustave Roussy
-
-
-
-
-
Jerusalem, Israel
- Sharett Institute of Oncology - Hadassah Hebrew University Medical Center
-
Tel Aviv, Israel
- Sheba Medical Center
-
Tel Aviv, Israel
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Aviano, Italien
- Oncological Center CRO
-
Bergamo, Italien
- Azienda Ospedaliera "Papa Giovanni XXIII"
-
Candiolo, Italien
- Candiolo Cancer Center (IRCCS)
-
Genova, Italien
- Policlinico San Martino - IRCCS per l'Oncologia
-
Milan, Italien
- European Institute of Oncology
-
Modena, Italien
- Azienda Ospedaliero-Universitaria Policlinico, University of Modena and Reggio Emilia
-
Padova, Italien
- IOV (Istituto Oncologico Veneto)
-
Pavia, Italien
- IRCCS Policlinico San Matteo
-
Roma, Italien
- AOU Policlinico Umberto I
-
-
-
-
-
Mexico City, Mexico
- Instituto Nacional de Cancerologia
-
-
-
-
-
Warsaw, Polen
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
-
-
-
-
Lisbon, Portugal
- Hospital de Santa Maria and Instituto de Medicina Molecular of the Faculty of Medicine of the University of Lisbon
-
-
-
-
-
Lugano, Schweiz
- Oncology Institute of Southern Switzerland
-
-
-
-
-
Barcelona, Spanien
- Vall d'Hebron University Hospital
-
Palma De Mallorca, Spanien
- Hospital Universitari Son Espases Palma
-
Valencia, Spanien
- INCLIVA, University Hospital of Valencia
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 40 år (Voksen)
Tager imod sunde frivillige
N/A
Køn, der er berettiget til at studere
Kvinde
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
Patients with diagnosis of invasive breast cancer between January 2000 and December 2012 at the age of ≤ 40 years and with known presence of germline BRCA mutation.
Beskrivelse
Inclusion Criteria:
- Diagnosis of invasive breast cancer between January 2000 and December 2012;
- Breast cancer diagnosis at the age of ≤ 40 years;
- Known presence of germline BRCA mutation.
Exclusion Criteria:
- Known BRCA mutation with no diagnosis of invasive breast cancer;
- Diagnosis of ovarian cancer or other malignancies with no history of invasive breast cancer;
- Diagnosis of hereditary or familiar invasive breast cancer without BRCA mutation or with BRCA genes not tested.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Tilbagevirkende kraft
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Pregnant cohort
Women with one or more pregnancies any time after breast cancer diagnosis
|
Clinical outcomes
|
Non-pregnant cohort
Women with no subsequent pregnancies after breast cancer diagnosis
|
Clinical outcomes
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of participants with a pregnancy following breast cancer diagnosis
Tidsramme: 10 years
|
The incidence of pregnancy following breast cancer diagnosis will be computed as the ratio between the number of breast cancer survivors in the pregnant cohort and the total number of eligible patients included in the study.
|
10 years
|
Disease-free survival and overall survival
Tidsramme: 10 years
|
To evaluate the prognostic impact of pregnancy following breast cancer diagnosis in BRCA mutated survivors, two survival endpoints will be compared between patients with and without a pregnancy following breast cancer diagnosis: disease-free survival and overall survival.
Disease-free survival event is defined by the occurrence of one of the following invasive events: local recurrence, distant metastases, contralateral or ipsilateral breast tumor, second primary malignancy, or death from any cause.
Overall survival event is defined as death from any cause.
|
10 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of pregnancies resulting in live birth and number of children born
Tidsramme: 10 years
|
Descriptive analysis aiming to evaluate the pregnancy, fetal and obstetrical outcomes of the pregnancies following breast cancer diagnosis in BRCA mutated survivors
|
10 years
|
Number of pregnancies resulting in induced and spontaneous abortion
Tidsramme: 10 years
|
Descriptive analysis aiming to evaluate the pregnancy, fetal and obstetrical outcomes of the pregnancies following breast cancer diagnosis in BRCA mutated survivors
|
10 years
|
Number of pregnancies resulting in pregnancy complications (if any)
Tidsramme: 10 years
|
Descriptive analysis aiming to evaluate the pregnancy, fetal and obstetrical outcomes of the pregnancies following breast cancer diagnosis in BRCA mutated survivors
|
10 years
|
Number of pregnancies resulting in fetal complication and/or congenital malformations (if any)
Tidsramme: 10 years
|
Descriptive analysis aiming to evaluate the pregnancy, fetal and obstetrical outcomes of the pregnancies following breast cancer diagnosis in BRCA mutated survivors
|
10 years
|
Number of pregnancies resulting in obstetrical complications (if any)
Tidsramme: 10 years
|
Descriptive analysis aiming to evaluate the pregnancy, fetal and obstetrical outcomes of the pregnancies following breast cancer diagnosis in BRCA mutated survivors
|
10 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
16. januar 2017
Primær færdiggørelse (Forventet)
1. juni 2019
Studieafslutning (Forventet)
1. juni 2023
Datoer for studieregistrering
Først indsendt
13. september 2018
Først indsendt, der opfyldte QC-kriterier
14. september 2018
Først opslået (Faktiske)
17. september 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
17. september 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. september 2018
Sidst verificeret
1. september 2018
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IJB-BRCAPreg-CE2630
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Uafklaret
IPD-planbeskrivelse
Undecided
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien
Kliniske forsøg med Clinical outcomes
-
Madigan Army Medical CenterTelemedicine & Advanced Technology Research Center; Analytics4Medicine,...UkendtUkontrolleret hypertensionForenede Stater
-
Mahidol UniversityUniversity of Medical Technology, YangonAfsluttetKognitiv forandringMyanmar
-
BC Centre for Improved Cardiovascular HealthUniversity of British ColumbiaUkendt
-
Thomas Jefferson UniversityAfsluttetHæmatopoietisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForenede Stater
-
University of MiamiRekruttering
-
Linkoeping UniversityAktiv, ikke rekrutterendeMyokardieinfarkt | SkrøbelighedSverige
-
University of SaskatchewanNovartis; Lung Association of SaskatchewanUkendtLungesygdom, kronisk obstruktivCanada
-
NuvoAir Medical PCRekrutteringKOL | Komorbiditeter og sameksisterende tilstandeForenede Stater
-
Aifred HealthMcGill UniversityAfsluttet
-
AVeta MedicalAfsluttet